BR112017019731A2 - compostos heterocíclicos tricíclicos úteis como inibidores de tnf - Google Patents
compostos heterocíclicos tricíclicos úteis como inibidores de tnfInfo
- Publication number
- BR112017019731A2 BR112017019731A2 BR112017019731-6A BR112017019731A BR112017019731A2 BR 112017019731 A2 BR112017019731 A2 BR 112017019731A2 BR 112017019731 A BR112017019731 A BR 112017019731A BR 112017019731 A2 BR112017019731 A2 BR 112017019731A2
- Authority
- BR
- Brazil
- Prior art keywords
- cr3r3
- heterocyclic compounds
- compounds useful
- tricyclic heterocyclic
- tnf inhibitors
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101150033527 TNF gene Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134779P | 2015-03-18 | 2015-03-18 | |
| US62/134,779 | 2015-03-18 | ||
| PCT/US2016/022738 WO2016149437A1 (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017019731A2 true BR112017019731A2 (pt) | 2018-05-22 |
Family
ID=55640933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017019731-6A BR112017019731A2 (pt) | 2015-03-18 | 2016-03-17 | compostos heterocíclicos tricíclicos úteis como inibidores de tnf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10308652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3271361B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6793658B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102630010B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107635992B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016233289A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017019731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2982446A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA032314B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2797685T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL254520A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017011433A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201707471RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016149437A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707473VA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Heterocyclic compounds useful as inhibitors of tnf |
| AU2016233288A1 (en) | 2015-03-18 | 2017-11-09 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| UY36630A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| TW201706258A (zh) | 2015-04-17 | 2017-02-16 | 艾伯維有限公司 | 作為ｔｎｆ信號傳遞調節劑之吲唑酮 |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| JP6811233B2 (ja) | 2015-08-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆアルファの修飾因子として有用な環状化合物 |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| US10953019B2 (en) | 2017-03-15 | 2021-03-23 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| ATE238998T1 (de) | 1997-02-25 | 2003-05-15 | Us Gov Health & Human Serv | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| EP1224185B1 (en) * | 1999-10-27 | 2005-11-30 | Novartis AG | Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| WO2003064422A1 (en) | 2002-01-31 | 2003-08-07 | Daiichi Pharmaceutical Co., Ltd. | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| EP2209785A1 (en) | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| EA028626B1 (ru) | 2012-06-11 | 2017-12-29 | Юсб Байофарма Спрл | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| WO2014072261A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Triazolo compounds |
| ES2529865B8 (es) * | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| WO2015086523A1 (en) | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9920052B2 (en) | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201702759XA (en) | 2014-10-06 | 2017-05-30 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| SG11201707473VA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Heterocyclic compounds useful as inhibitors of tnf |
| AU2016233288A1 (en) | 2015-03-18 | 2017-11-09 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| UY36630A (es) * | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| CA2980100A1 (en) * | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
-
2016
- 2016-03-17 MX MX2017011433A patent/MX2017011433A/es unknown
- 2016-03-17 AU AU2016233289A patent/AU2016233289A1/en not_active Abandoned
- 2016-03-17 KR KR1020177029450A patent/KR102630010B1/ko active Active
- 2016-03-17 US US15/558,708 patent/US10308652B2/en active Active
- 2016-03-17 JP JP2017549093A patent/JP6793658B2/ja active Active
- 2016-03-17 WO PCT/US2016/022738 patent/WO2016149437A1/en not_active Ceased
- 2016-03-17 CN CN201680025154.3A patent/CN107635992B/zh active Active
- 2016-03-17 CA CA2982446A patent/CA2982446A1/en not_active Abandoned
- 2016-03-17 EP EP16712646.5A patent/EP3271361B1/en active Active
- 2016-03-17 BR BR112017019731-6A patent/BR112017019731A2/pt not_active Application Discontinuation
- 2016-03-17 ES ES16712646T patent/ES2797685T3/es active Active
- 2016-03-17 EA EA201792025A patent/EA032314B1/ru not_active IP Right Cessation
- 2016-03-17 SG SG11201707471RA patent/SG11201707471RA/en unknown
-
2017
- 2017-09-15 IL IL254520A patent/IL254520A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016233289A1 (en) | 2017-11-09 |
| ES2797685T3 (es) | 2020-12-03 |
| JP6793658B2 (ja) | 2020-12-02 |
| IL254520A0 (en) | 2017-11-30 |
| CN107635992B (zh) | 2020-05-22 |
| KR20170129811A (ko) | 2017-11-27 |
| SG11201707471RA (en) | 2017-10-30 |
| JP2018508554A (ja) | 2018-03-29 |
| EP3271361B1 (en) | 2020-04-22 |
| MX2017011433A (es) | 2017-11-10 |
| EA032314B1 (ru) | 2019-05-31 |
| US20180111937A1 (en) | 2018-04-26 |
| CA2982446A1 (en) | 2016-09-22 |
| EP3271361A1 (en) | 2018-01-24 |
| WO2016149437A1 (en) | 2016-09-22 |
| CN107635992A (zh) | 2018-01-26 |
| KR102630010B1 (ko) | 2024-01-25 |
| US10308652B2 (en) | 2019-06-04 |
| EA201792025A1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017019731A2 (pt) | compostos heterocíclicos tricíclicos úteis como inibidores de tnf | |
| BR112018001960A2 (pt) | compostos heterocíclicos úteis como moduladores de tnf alfa | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| EA202091483A1 (ru) | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr | |
| BR112017019773A2 (pt) | compostos heterocíclicos tricíclicos substituídos | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| BR112019023290A2 (pt) | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA201792047A1 (ru) | Новые соединения | |
| BR112017019605A2 (pt) | compostos heterocíclicos úteis como inibidores de tnf | |
| BR112018001980A2 (pt) | compostos cíclicos úteis como moduladores de tnf alfa | |
| BR112015028017A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CL2016001364A1 (es) | Moduladores de ror gamma (rory) | |
| MX2016015743A (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa. | |
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| EA201991029A1 (ru) | Ингибиторы magl | |
| MX376163B (es) | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |